Regulus Therapeutics (RGLS) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts RGLS Hot Sheet
Join SI Premium – FREE
Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
